CHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it will release its financial results for the second quarter and first half ended June 30, 2022, on Monday, August 15, 2022. Vyant Bio will host an investor conference call and webcast on Monday, August 15, 2022 at 4:30 pm ET.
Vyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/The%20sign%20for%20Marvell%20Technology%20out%20front%20of%20a%20corporate%20office%20by%20Valeriya%20Zankovych%20via%20Shutterstock.jpg)
/Microsoft%20Corporation%20logo%20on%20sign-by%20Jean-Luc%20Ichard%20via%20iStock.jpg)
